Get the Stockscreener App
90.95
0.65%
0.495
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $90.95, with a volume of 55,315.
It is up +0.65% in the last 24 hours and up +0.83% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$90.46
Open:
$90.67
24h Volume:
55,315
Relative Volume:
0.04
Market Cap:
$10.17B
Revenue:
$2.86B
Net Income/Loss:
$239.88M
P/E Ratio:
43.51
EPS:
2.0903
Net Cash Flow:
$506.94M
1W Performance:
+2.37%
1M Performance:
+0.83%
6M Performance:
+3.12%
1Y Performance:
-2.12%
1-Day Range:
$89.75
$91.06
1-Week Range:
$86.23
$92.99
52-Week Range:
$81.36
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
91.00 | 10.11B | 2.86B | 239.88M | 506.94M | 2.0903 |
TMO
Thermo Fisher Scientific Inc
|
502.84 | 187.10B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
192.40 | 138.84B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
572.61 | 47.01B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.62 | 33.04B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
320.21 | 31.25B | 3.17B | 642.63M | 516.49M | 10.77 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity (RVTY) Introduces New Cloud-Based Molecular Cloning Plat - GuruFocus
Revvity launches cloud-based molecular cloning software platform By Investing.com - Investing.com South Africa
Revvity (RVTY) Launches Cloud-Based Molecular Cloning Solution - GuruFocus
Revvity Launches Signals BioDesign Offering for Biologics Research Workflows - marketscreener.com
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows - Yahoo Finance
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Swing Trade: Can Revvity Inc outperform in the next rallyLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Revvity Sees Growth in Diagnostics, Encounters Challenges in China - Bitget
Revvity Gains on Diagnostics Strength, Faces China Headwinds - TradingView
Evercore ISI Adjusts Revvity Price Target to $108 From $118, Maintains Outperform Rating - marketscreener.com
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $108 - Moomoo
Tudor Investment Corp ET AL Purchases Shares of 172,601 Revvity Inc. $RVTY - MarketBeat
Revvity (RVTY) Valuation Check After Recent Share Price Momentum Shift - Yahoo Finance
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
META_TITLE_QUOTE - Yahoo Finance Singapore
Revvity at TD Cowen: Strategic Growth and Margin Expansion - Investing.com
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance UK
Baird Maintains Revvity (RVTY) Outperform Recommendation - MSN
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo Finance
Here’s Artisan Mid Cap Value Fund’s Investment Thesis for Revvity (RVTY) - Yahoo Finance
Revvity Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Liquidity Mapping Around (RVTY) Price Events - Stock Traders Daily
Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’ - MSN
JP Morgan Lowers Revvity (RVTY) Price Target to $96, Maintains N - GuruFocus
Revvity (NYSE:RVTY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Initiates Revvity(RVTY.US) With Hold Rating, Announces Target Price $96 - Moomoo
JPMorgan Adjusts Price Target on Revvity to $96 From $105, Maintains Neutral Rating - marketscreener.com
Allspring Global Investments Holdings LLC Raises Holdings in Revvity Inc. $RVTY - MarketBeat
RVTY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Revvity Inc (RVTY) Shares Gap Down to $83.9 on Mar 30 - GuruFocus
Stifel maintains a hold rating on Revvity (RVTY) - MSN
Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap - Sahm
SG Americas Securities LLC Boosts Stock Holdings in Revvity Inc. $RVTY - MarketBeat
Revvity stock price forecast: persistent downtrend and oversold signals as RVTY nears 52-week low - Traders Union
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard disaggregates holdings; Revvity (RVTY) filing shows 0 shares - Stock Titan
Stifel Maintains a Hold Rating on Revvity (RVTY) - Insider Monkey
Revvity Inc. Stock: Navigating Life Sciences Headwinds and Q4 Earnings Pressure Ahead - AD HOC NEWS
Here's why you should retain Revvity stock in your portfolio for now - MSN
Revvity Inc. stock faces pressure amid life sciences sector slowdown as Q4 earnings loom - AD HOC NEWS
EdgePoint Investment Group Inc.'s Revvity Inc(RVTY) Holding History - GuruFocus
10 Best Mid Cap Value Stocks to Buy in 2026 - Insider Monkey
Research Alert: CFRA Maintains Buy Rating On Shares Of Revvity, Inc. - Moomoo
Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test - AD HOC NEWS
Is Revvity stock underperforming the S&P 500? - MSN
Revvity Inc. stock faces pressure amid life sciences sector slowdown and acquisition integration cha - AD HOC NEWS
Bull Bear: Can Revvity Inc outperform in the next rally2026 Weekly Recap & Weekly Watchlist of Top Performers - baoquankhu1.vn
Why is Revvity (RVTY) down 5.1% since last earnings report? - MSN
Revvity, Inc. (RVTY) Stock forecasts - Yahoo Finance UK
Is Revvity Inc a play on infrastructure spendingMarket Performance Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):